• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Janux Therapeutics

skydiving mountain parachute
Biotech

Takeda taps Julie Kim as new CEO—Chutes & Ladders

Takeda taps Kim as new CEO. Kailera goes commercial with Lilly vet. Roche adds technology officer to executive team.
Darren Incorvaia , Zoey Becker Jan 31, 2025 8:30am
cancer cell lymphocytes T cells cancer

Janux's T-cell engager makes waves, again, with new data drop

Dec 3, 2024 11:40am
An artists concept of T cells attacking a cancer cell The T cells are in red while the cancer is light blue The cells are

Janux's shares jump 130% following T-cell engager data drop

Feb 27, 2024 10:35am
signing contract

Merck-partnered Janux hires CMO as its bispecifics near clinic

Jun 4, 2021 8:05am
Janux CEO David Campbell

Janux seeks $100M IPO on preclinical promise of bispecifics

May 21, 2021 6:55am
Janux CEO David Campbell

Janux raises $56M to take safer T-cell engagers into the clinic

Mar 3, 2021 8:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings